We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
Piperlongumine is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Piperlongumine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality studies published 2013–2026.
Based on 18 studies
Confidence
LowBy outcome
Piperlongumine has an evidence score of 3/10 — emerging evidence based on 18 indexed studies. A natural alkaloid from long pepper (Piper longum), studied as a senolytic and ROS-raising anticancer agent. It selectively kills senescent 'zombie' cells and cancer cells in petri dishes and mice, but ALL of this is preclinical — there is no human efficacy data, and its very poor oral bioavailability is a major limit. A research compound, not a supplement or drug. Representative study: PMID 27913811.
The commonly studied dose of Piperlongumine is No validated human dose exists. All dosing is preclinical (cell-culture micromolar concentrations or mg/kg in mice). Piperlongumine is a research chemical with poor oral bioavailability — there is no established or safe human regimen, and it is not appropriate for self-administration.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Last reviewed June 2026 · evidence from 18 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Piperlongumine (piplartine) — natural senolytic research compound
A natural alkaloid from long pepper (Piper longum), studied as a senolytic and ROS-raising anticancer agent. It selectively kills senescent 'zombie' cells and cancer cells in petri dishes and mice, but ALL of this is preclinical — there is no human efficacy data, and its very poor oral bioavailability is a major limit. A research compound, not a supplement or drug.
Piperlongumine is a natural alkaloid with a well-characterized senolytic / ROS-raising mechanism and abundant in-vitro and mouse evidence for selectively killing senescent and cancer cells — but ALL of it is preclinical, there is no human efficacy data of any kind, and poor/variable oral bioavailability is a major translational barrier. It is a research compound, not an established supplement or drug, so the score is low.
Piperlongumine (also called piplartine, 'PL') is a biologically active amide alkaloid isolated from long pepper (Piper longum), a plant long used in Ayurvedic medicine. It has become a research compound of interest in two overlapping fields: cancer biology and geroscience.
Mechanistically, PL is a redox modulator — it raises intracellular reactive-oxygen-species (ROS) selectively in stressed cells by binding and depleting antioxidant defenses (it degrades oxidation-resistance protein OXR1 in senescent cells and lowers glutathione / GST activity in cancer cells), tipping those cells, but not healthy ones, into apoptosis.
In geroscience it was identified in 2016 as a second-generation senolytic in the same screen that produced ABT-263/navitoclax: it preferentially killed senescent human fibroblasts (induced by radiation, replicative exhaustion, or oncogenic Ras) and synergized with navitoclax.
In oncology, decades of in-vitro and mouse-xenograft work show selective cytotoxicity across many cancer-cell types, tumor-growth inhibition in mice, and sensitization to chemotherapy (e.g. cisplatin). The honest picture is firmly preclinical.
There are no human efficacy trials of piperlongumine for cancer, senescence, or aging — the evidence is in petri dishes and mice.
Its drug-like properties are poor: low aqueous solubility and poor/variable oral bioavailability are repeatedly flagged as the central translational barrier, which is why much current work is on nanoformulations and synthetic analogs rather than the parent molecule.
It is also a genotoxic, pro-oxidant cytotoxic compound, not a benign botanical extract. Piperlongumine is a research chemical used as a laboratory tool; it is not an established supplement or approved drug, and self-administration is not supported by any human evidence.
The score reflects a genuinely interesting, well-characterized preclinical mechanism set against zero human data and poor bioavailability.
Piperlongumine raises reactive-oxygen-species selectively in stressed cells by depleting antioxidant defenses (glutathione / GST), tipping cancer cells — but not normal cells — toward apoptosis.
In senescent cells it binds and degrades oxidation-resistance protein 1 (OXR1), an antioxidant regulator they over-express to survive, selectively killing them — the identified senolytic mechanism.
Downstream it engages intrinsic apoptosis and modulates PI3K/AKT/mTOR, NF-κB, STAT, and JNK/PARP signaling in cancer-cell models.
How Piperlongumine works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose exists. All dosing is preclinical (cell-culture micromolar concentrations or mg/kg in mice). Piperlongumine is a research chemical with poor oral bioavailability — there is no established or safe human regimen, and it is not appropriate for self-administration.
Can be taken without food
| Form | Type |
|---|---|
| 💊None established (preclinical research compound) | Recommended |
| 💊Other senolytics with more (still limited) evidence — fisetin, dasatinib + quercetin, navitoclax | Alternative |
An in-vitro / animal research compound used as a laboratory tool — not available or validated as a supplement.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: Research compound; no validated human timing or schedule exists.
Dose-response data unavailable. The current published research for Piperlongumine does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Preferentially killed senescent human fibroblasts and synergized with navitoclax in cell models — not shown in animals' aging or in humans.
Selectively cytotoxic to many cancer-cell types and inhibited tumor growth in mouse xenografts — preclinical only.
There are no human trials of piperlongumine for cancer, senescence, or aging — the evidence stops at mice.
Low solubility and poor/variable oral bioavailability are the central translational barrier; nanoformulations and analogs are being developed to work around it.
Research-use-only; not validated or safe to self-administer.
Avoid — genotoxic, cytotoxic research compound.
Avoid self-use — documented preclinical interactions and no human safety data.
In cell studies, antioxidants block piperlongumine's ROS-mediated cytotoxicity — i.e. they oppose its proposed mechanism (preclinical observation).
Synergized with cisplatin in preclinical cancer models — a research finding, not a validated human combination.
Tip: It is a cytotoxic, genotoxic, pro-oxidant compound by design; human safety is uncharacterized. Human frequency is unquantified — this is a preclinical/mechanistic risk, not a measured clinical rate.
Timing is flexible for Piperlongumine — consistent daily use matters more than the time of day. Research compound with no human pharmacology; any reported dosing is from cell or mouse studies.
Piperlongumine should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are pro-oxidant / genotoxic cytotoxicity. Use caution if any of these apply to you: Any non-research human use; Pregnancy / breastfeeding; Concurrent chemotherapy or other cytotoxic agents (research interactions only).
Fermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.